| A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT07751341) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-08-01 |
| The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer (NCT07704645) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-08-01 |
| A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer (NCT07735377) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-08-01 |
| A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma (NCT07661537) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-23 |
| A Clinical Study of SHR-5421 in Patients With Multiple Myeloma (NCT07652281) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-23 |
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (NCT07424287) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-13 |
| A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC (NCT07726992) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-01 |
| A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer (NCT07676162) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-01 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer (NCT07679360) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-01 |
| A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors (NCT07676903) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-01 |
| A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma (NCT07682272) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-01 |
| A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer (NCT07489716) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-04-29 |
| A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (NCT07478302) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-04-14 |
| A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer (NCT07418749) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-03-30 |
| A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer (NCT07450976) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-03-25 |
| A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (NCT07454720) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-03-23 |
| A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects (NCT07414602) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-03-16 |
| A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors (NCT07229638) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-02-27 |
| A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma (NCT07393542) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-02-12 |
| A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (NCT07229625) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-01-21 |
| A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors (NCT07298772) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-01-07 |
| Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (NCT07239596) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-01-06 |
| A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor (NCT07275242) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-12-23 |
| A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors (NCT07229612) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-12-03 |
| A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC (NCT07183189) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-10-30 |
| Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT07170995) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-10-22 |
| A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (NCT07110571) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-08-28 |
| A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors (NCT07123129) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-08-28 |
| A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (NCT07111832) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-08-20 |
| A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07118527) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-08-18 |
| A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (NCT07071714) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-07-22 |
| A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors (NCT07068932) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-07-22 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (NCT07059221) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-07-11 |
| A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (NCT07028281) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-07-08 |
| A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors (NCT07028268) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-06-24 |
| A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer (NCT07009457) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-06-16 |
| A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis (NCT06860750) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-29 |
| SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (NCT06859775) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-25 |
| Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) (NCT06879145) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-25 |
| A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma (NCT06929624) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-24 |
| A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors (NCT06907628) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-02 |
| A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (NCT06840002) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-03-18 |
| A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC (NCT06844474) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-03-07 |
| A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer (NCT06778031) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-26 |
| A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (NCT06703177) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-18 |
| A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (NCT06754930) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-18 |
| The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis (NCT06833307) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-01 |
| Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis (NCT06779097) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-02-01 |
| A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors (NCT06737731) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-01-21 |
| A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (NCT06671379) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-11-29 |
| A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors (NCT06618651) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-11-13 |
| A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis (NCT06640257) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-11-04 |
| A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (NCT06618664) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-10-28 |
| Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (NCT06434103) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-10-10 |
| Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients (NCT06592625) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-09-20 |
| A Clinical Study of SHR-9539 in Patients With Multiple Myeloma (NCT06484777) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-08-07 |
| SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer (NCT06465563) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-07-01 |
| A Trial of SHR-4849 in Advanced Solid Tumors (NCT06443489) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-06-26 |
| The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors (NCT06381050) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-05-24 |
| PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases (NCT06380881) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-05-20 |
| SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (NCT06394492) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-05-10 |
| Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (NCT06247956) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-03-11 |
| Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan (NCT06199973) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-03-01 |
| A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer (NCT06211023) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-02-15 |
| An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors (NCT06094556) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-12-25 |
| A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices (NCT06182384) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-12-24 |
| Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors (NCT06131216) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-12-01 |
| Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors (NCT06059508) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-10-25 |
| A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors (NCT06092268) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-10-01 |
| A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. (NCT05845138) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-07-25 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women (NCT05930704) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-07-04 |
| Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (NCT05671822) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-03-14 |
| Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors (NCT05765032) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-12-30 |
| Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer (NCT05503888) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-10-01 |
| Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients (NCT05394857) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-09-13 |
| Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer (NCT05416775) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-08-15 |
| The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (NCT05394818) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-07-21 |
| SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer (NCT05300269) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-07-05 |
| A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers (NCT05349409) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-06-09 |
| A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer (NCT05179239) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-02-26 |
| A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients (NCT05198817) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-02-22 |
| A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors (NCT05193721) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-02-10 |
| Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer (NCT05149807) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-01-26 |
| A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer (NCT05134194) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-01-17 |
| A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (NCT05114759) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-01-04 |
| A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours (NCT05154604) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-12-31 |
| A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer (NCT05132413) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-12-30 |
| A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (NCT04950322) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-12-06 |
| Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis (NCT05055934) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-10-22 |
| Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors (NCT04974957) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-08-30 |
| A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis (NCT04924296) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-06-28 |
| A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC (NCT04856787) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-06-22 |
| Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis (NCT04840485) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-06-09 |
| Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors (NCT04856774) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-06-01 |